Pfizer (PFE) Intangibles (2009 - 2026)

Pfizer (PFE) has reported Intangibles for 18 consecutive years, with $47.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Intangibles fell 10.72% year-over-year to $47.1 billion in Q2 2026; TTM through Jun 2026 was $47.1 billion, a 10.72% decrease from a year earlier, with the FY2025 full-year figure at $53.7 billion, down 3.03% from the prior year.
• Intangibles was $47.1 billion for Q2 2026 at Pfizer, down from $52.6 billion in the prior quarter.
• Over five years, Intangibles peaked at $64.9 billion in Q4 2023 and troughed at $29.1 billion in Q3 2022.
• A 5-year average of $50.1 billion and a median of $52.6 billion in 2025 frame the typical range for Intangibles.
• Across the five-year window, Intangibles soared 72.47% in 2022 and dropped 14.62% in 2024, its largest moves.
• Over 5 years, Intangibles stood at $43.4 billion in 2022, then soared by 49.64% to $64.9 billion in 2023, then decreased by 14.62% to $55.4 billion in 2024, then fell by 3.03% to $53.7 billion in 2025, then declined by 12.43% to $47.1 billion in 2026.
• The last three Intangibles figures came in at $47.1 billion (Q2 2026), $52.6 billion (Q1 2026), and $53.7 billion (Q4 2025), per Business Quant data.